Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
SEK 1.42
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable price performance
Data is available to registered users only
Data is available to registered users only
About
NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks.
Data is available to registered users only
Buy
Sell